Oseltamivir is devoid of specific behavioral and other central nervous system effects in juvenile rats at supratherapeutic oral doses

International Journal of Virology

Volumn 5, Issue 3, 2009, Pages 119-130

  Freichel, C ^a   Prinssen, E ^b   Hoffmann, G ^a   Gand, L ^a   Beck, M ^c   Weiser, T ^a   Breidenbach, A ^a  

^a Non Clinical Safety   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c WIL RESEARCH LABORATORIES   (United States)

Author keywords

Behavioral effects; Central nervous system; Oseltamivir; Toxicokinetics; Toxicology

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BODY POSTURE; CONTROLLED STUDY; CONVULSION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG SAFETY; FEMALE; JUVENILE ANIMAL; MALE; NEUROTOXICITY; NONHUMAN; RAT; TOXICITY TESTING; TOXICOKINETICS; TREMOR;

ANIMALIA; RATTUS;

EID: 77955351639     PISSN: 18164900     EISSN: None     Source Type: Journal    
DOI: 10.3923/ijv.2009.119.130     Document Type: Article

References (18)

1. Bhat, N., J.G. Wright, K.R. Broder, E.L. Murray, M.E. Greenberg and M.J. Glover et al., 2005. Influenza-associated deaths among children in the United States, 2003-2004. N. Engl. J. Med., 353: 2559-2567.
2. Doucette, K.E. and F.Y. Aoki, 2001. Oseltamivir: A clinical and pharmacological perspective. Expert Opin. Pharmacother., 2: 1671-1683.
3. Drago, F., L.F. Di and L. Giardina, 1999. Prenatal stress induces body weight deficit and behavioural alterations in rats: The effect of diazepam. Eur. Neuropsychopharmacol., 9: 239-245.
4. Gad, S.C., 1982. A neuromuscular screen for use in industrial toxicology. J. Toxicol. Environ. Health, 9: 691-704.
5. Haggerty, G.C., 1989. Development of tier I neurobehavioral testing capabilities for incorporation into pivotal rodent safety assessment studies. J. Am. Coll. Toxicol., 8: 53-69.
6. He, G., J. Massarella and P. Ward, 1999. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet., 37: 471-484.
7. Irwin, S., 1968. Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacol. Berl, 13: 222-257.
8. Izurieta, H.S., W.W. Thompson, P. Kramarz, D.K. Shay and R.L. Davis et al., 2000. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N. Engl. J. Med., 342: 232-239.
9. Moser, V.C., J.P. McCormick, J.P. Creason and R.C. MacPhail, 1988. Comparison of chlordimeform and carbaryl using a functional observational battery. Fundam. Applied Toxicol., 11: 189-206.
10. Moser, V.C., K.L. McDaniel and P.M. Phillips, 1991. Rat strain and stock comparisons using a functional observational battery: Baseline values and effects of amitraz. Toxicol. Applied Pharmacol., 108: 267-283.
11. National Research Council, 1996. Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington, DC., USA., ISBN-10: 0-309-05377-3.
12. Neuzil, K.M., B.G. Mellen, P.F. Wright, E.F. Mitchel Jr. and M.R. Griffin, 2000. The effect of influenza on hospitalizations, outpatient visits and courses of antibiotics in children. N. Engl. J. Med., 342: 225-231.
13. O'Donoghue, J.L., 1989. Screening for neurotoxicity using neurologically based examination and neuropathy. J. Am. Coll. Toxicol., 8: 97-115.
14. Ose, A., H. Kusuhara, K. Yamatsugu, M. Kanai, M. Shibasaki, T. Fujita, A. Yamamoto and Y. Sugiyama, 2008. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier. Drug Metab. Dispos., 36: 427-434.
15. Shi, D., J. Yang, D. Yang, E.L. LeCluyse, C. Black, L. You, F. Akhlaghi and B. Yan, 2006. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J. Pharmacol. Exp. Ther., 319: 1477-1484.
16. US Environmental Protection Agency, 1996. Reference Manual for a Functional Observational Battery. Section III, US Environmental Protection Agency, Washington, DC. USA., pp: 11.
17. US Environmental Protection Agency, 1998. Guidelines for Neurotoxicity Risk Assessment. Document EPA/630/R-95/001F, US Environmental Protection Agency, Washington, DC. USA.
18. Watson, R.E., J.M. Desesso, M.E. Hurtt and G.D. Cappon, 2006. Postnatal growth and morphological development of the brain: A species comparison. Birth. Defects Res. B. Dev. Reprod. Toxicol., 77: 471-484.